Dr David Gilligan

BSc (Hons), MB BChir, FRCP (Edin), FRCR


  • Specialities Medical Oncology
  • Telephone 01223 370 922
  • Year of first qualification 1985
  • Email
  • Languages spoken

    English

  • GMC Number 3122095
  • Fax 01223 281 310

Profile

David Gilligan is a Consultant Oncologist in the Thoracic Oncology Unit at Addenbrookes and Papworth Hospitals in Cambridge. He is also the Divisional Director for Cancer at Addenbrookes and a Recognized Clinical Teacher at the University of Cambridge School of Clinical Medicine. He trained in Oncology at The Christie Hospital, Manchester and in London at The Royal Marsden Hospital and University College Hospitals. His main clinical and research interests are in all aspects of thoracic oncology and oesophago-gastric tumours. He is a specialist advisor to Cancer Backup and CancerHelpUK, the patient information arm of Cancer Research UK.


Clinics

  • Weekly Monday 17:30 - 20:00

Locations

Current posts

  • Consultant, Addenbrookes NHS Trust Hospital Cambridge and Papworth Hospital Cambridgeshire

Interests

Other interests

Recent publications include:

  1. Gilligan D , Nicholson M, Smith I, Greon H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit h, van Meerbeeck H, Nankivell M, Parmar M, Pugh C and Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of sytematic review. Lancet(2007) 369: 1929-37
  2. Lee SM, James L, Qian W, Spiro S, Eisen T, Gower N, Ferry D, Gilligan D, Harper P, Prendiville J, Hocking M and Rudd R. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax (2008) Sep 11 [Epub ahead of print]
  3. Chaudhray MS, Waters M, and Gilligan D Paraneoplatic limbic encephalitis attributable to thymoma Journal of Thoracic Oncology (2007) 2:879-80
  4. Treece SJ, Magee L, Gilligan D and Harden SV Adjuvant chemotherapy in non-smallcell lung cancer - how feasible is it in a non-trial population Clinical Oncology (2007) 19:629-30
  5. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Riuz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK,; London Lung Cancer Group Early compared with lete radiotherapy in combined modality treatment for limited disease small cell lung cancer:  a London Lung Cancer Group mutlicenter trial and meta-analysis Journal of Clinical Oncology (2006) 24:3823-530

Member of

  • Royal College of Physicians
  • Royal College of Radiologists
  • British Thoracic Oncology Group
  • International Association for Study of Lung Cancer
  • Medical Defence Union